MaxCyte IPO Presentation Deck

A Single Delivery Platform for Cell Engineering from Concept to Clinic ATX Concept DOE Optimization Verification Proof of Concept: No large scalability needed ATX primarily used July 2021 GTX Optimization/Verification: ATX or GTX used Option to secure annual research license or purchase the instrument Phase I No clinical/commercial rights or access to-FDA Master File/Technical Files SPL required when the program reaches IND stage. Pivotal CONFIDENTIAL Validation CGMP Production in the Clinic: GTX used SPL required Access to IP and FDA Master File/Technical Files $250k annual license fee per instrument Approval On-Market GTX Approval/ On-Market: SPL required Sales-based payments (royalties in some cases) Access to IP and FDA Master File/Technical Files $250k annual license fee per instrument

View entire presentation